Yinuo Wu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8651334/publications.pdf

Version: 2024-02-01

29	604	516215 16	610482 24
papers	citations	h-index	g-index

29	29	29	751
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PDE1 inhibitors: a review of the recent patent literature (2008-present). Expert Opinion on Therapeutic Patents, 2022, 32, 423-439.	2.4	5
2	Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia. Acta Pharmaceutica Sinica B, 2022, 12, 3103-3112.	5.7	4
3	Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. Journal of Medicinal Chemistry, 2022, 65, 8444-8455.	2.9	6
4	Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimerâ€™s Disease. Molecules, 2021, 26, 3034.	1.7	8
5	Discovery of Highly Specific Catalytic-Site-Targeting Fluorescent Probes for Detecting Lysosomal PDE10A in Living Cells. ACS Chemical Biology, 2021, 16, 857-863.	1.6	1
6	Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. Journal of Medicinal Chemistry, 2021, 64, 9537-9549.	2.9	7
7	Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 128016.	1.0	6
8	Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 15852-15863.	2.9	9
9	Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry, 2020, 63, 7867-7879.	2.9	23
10	Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharmaceutica Sinica B, 2020, 10, 2339-2347.	5.7	17
11	Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. ACS Chemical Neuroscience, 2020, 11, 1058-1071.	1.7	7
12	Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127254.	1.0	6
13	Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor of Phosphodiesterase-10. Journal of Medicinal Chemistry, 2019, 62, 2099-2111.	2.9	47
14	Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 3707-3721.	2.9	26
15	Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2018, 61, 5467-5483.	2.9	83
16	Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 260-270.	2.5	19
17	Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors. Acta Pharmaceutica Sinica B, 2018, 8, 615-628.	5.7	20
18	Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities. Frontiers in Chemistry, 2018, 6, 167.	1.8	9

#	Article	IF	Citations
19	Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay. Journal of Chemical Information and Modeling, 2017, 57, 355-364.	2.5	40
20	Docking-assisted 3D-QSAR studies on xanthones as Î±-glucosidase inhibitors. Journal of Molecular Modeling, 2017, 23, 272.	0.8	9
21	Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 2522-2534.	1.7	29
22	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry, 2017, 60, 6622-6637.	2.9	34
23	Discovery of novel PDE9 inhibitors capable of inhibiting AÎ² aggregation as potential candidates for the treatment of Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 21826.	1.6	32
24	Discovery and modelling studies of natural ingredients from Gaultheria yunnanensi s (FRANCH.) against phosphodiesterase-4. European Journal of Medicinal Chemistry, 2016, 114, 134-140.	2.6	19
25	Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor. Molecular Pharmacology, 2015, 88, 836-845.	1.0	23
26	Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds. Molecular BioSystems, 2015, 11, 115-125.	2.9	21
27	Ab Initio QM/MM Study Shows a Highly Dissociated S_N2 Hydrolysis Mechanism for the cGMP-Specific Phosphodiesterase-5. Journal of Chemical Theory and Computation, 2014, 10, 5448-5457.	2.3	9
28	Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent. Journal of Medicinal Chemistry, 2014, 57, 10304-10313.	2.9	53
29	The Molecular Basis for the Selectivity of Tadalafil toward Phosphodiesterase 5 and 6: A Modeling Study. Journal of Chemical Information and Modeling, 2013, 53, 3044-3053.	2.5	32